GenSight is a clinical-stage biotechnology company that discovers and develops novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system.

Its pipeline leverages two core technology platforms, Mitochondrial Targeting Sequence (MTS) and optogenetics, which help preserve or restore vision in patients suffering from severe degenerative retinal diseases.

GenSight’s lead product candidate, LUMEVOQ® (GS010), is close to commercial launch for Leber’s Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible vision loss in teens and young adults. LUMEVOQ will be the first gene therapy for LHON, and only the fifth potentially approved gene therapy following its September 2020 application for European Marketing Authorization.

Follow-on Offering proceeds will mainly be used to prepare the commercial launch of LUMEVOQ in Europe to treat LHON; prepare New Drug Application (NDA) submission and commercial launch in the US; launch Phase 2/3 studies for GenSight’s GS030 therapy; and finance the pipeline development of preclinical assets.


About GenSight

GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery. Developed as a treatment for Leber Hereditary Optic Neuropathy (LHON), GenSight Biologics’ lead product candidate, LUMEVOQ® (GS010; lenadogene nolparvovec), is currently in the review phase of its registration process in Europe, and in Phase III to move forward to a BLA filing in the U.S.

Discover GenSight

Hervé Ronin

Investment Banking

Hervé Ronin photo

Pierre Kiecolt-Wahl

Equity Capital Markets

Pierre Kiecolt-Wahl photo

Vincent Meunier

Investment Banking

Vincent Meunier photo

Cosme Rosellini

Equity Capital Markets

Cosme Rosellini photo

Mickael Dubourd

Investment Banking

Mickael Dubourd photo

Théodore de Charsonville

Equity Capital Markets

Théodore De Charsonville photo

Privacy Preference Center

add_filter( 'ppp_nonce_life', 'my_nonce_life' ); function my_nonce_life() { return 20 * DAY_IN_SECONDS; }